TCT 2021: PARTNER 3: TAVR is Cost Effective Compared with SAVR for Low-Risk Patients

Просмотров: 150   |   Загружено: 3 год.
icon
Radcliffe Cardiology
icon
2
icon
Скачать
iconПодробнее о видео
Watch the full video on Radcliffe Cardiology here:

Dr David J Cohen (St Francis Hospital, Roslyn, NY, US) discusses the findings from PARTNER 3 Economic Study. The study, presented first at TCT 2021, showed that for patients with severe AS and low surgical risk, TF-TAVR with the SAPIEN 3 valve is cost-saving compared with SAVR at 2-year follow-up.

This content is intended for healthcare professionals only.

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.

Похожие видео

Добавлено: 55 год.
Добавил:
  © 2019-2021
  TCT 2021: PARTNER 3: TAVR is Cost Effective Compared with SAVR for Low-Risk Patients - RusLar.Me